Clinical Trials
2 trialsNCT06099821 2023-10-26
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT03271255 2019-01-23
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
Shenzhen People's Hospital
Phase 2 Unknown